CYCN (Cyclerion Therapeutics) Debt-to-Revenue : 0.00 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cyclerion Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cyclerion Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Cyclerion Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Cyclerion Therapeutics's annualized Revenue for the quarter that ended in Sep. 2024 was $0.78 Mil. Cyclerion Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.00.

Cyclerion Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Cyclerion Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclerion Therapeutics Debt-to-Revenue Chart

Cyclerion Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

16.40

19.92

N/A

Cyclerion Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	-

Competitive Comparison of Cyclerion Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Cyclerion Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclerion Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclerion Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cyclerion Therapeutics's Debt-to-Revenue falls into.

Cyclerion Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cyclerion Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	N/A
	=	N/A

Cyclerion Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0.776
	=	0.00

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Cyclerion Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cyclerion Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclerion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, 18th Floor, Cambridge, MA, USA, 02142

Website

https://www.cyclerion.com

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Executives

Slate Path Capital Lp	10 percent owner	717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman	director	C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch	officer: Chief Scientific Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades	director	500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson	director	CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell	director	C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht	director, officer: Chief Executive Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Errol B Desouza	director	215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino	officer: Chief Financial Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright	officer: Chief Medical Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault	officer: Chief Operating Officer	CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie	officer: President and CSO	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142